Company Filing History:
4 out of 8 
3 out of 26 
2 out of 63 
Years Active: 2016-2022
Title: Innovations of Gareth Harbottle
Introduction
Gareth Harbottle is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate p300 and CBP activity. With a total of seven patents to his name, Harbottle's work has the potential to impact cancer treatment significantly.
Latest Patents
One of Gareth Harbottle's latest patents is a process for preparing modulators of p300 and/or CBP. This process involves treating specific compounds to generate an intermediate compound, which is then further processed to recover a promising modulator of p300/CBP activity. This compound has potential utility in treating various cancers, including prostate cancer, haematological cancers, bladder cancer, and lung cancer. Another significant patent involves pharmaceutical compounds, specifically an arylimidazolyl isoxazole that modulates the activity of p300 and/or CBP, with a focus on treating prostate cancer.
Career Highlights
Throughout his career, Gareth Harbottle has worked with several companies, including Cellcentric Limited and Topivert Pharma Limited. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical sector.
Collaborations
Gareth has collaborated with notable individuals in his field, including David Michel, Adrien Taddei, and Thomas Matthew Baker. These collaborations have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
Gareth Harbottle's contributions to pharmaceutical innovations demonstrate his commitment to advancing cancer treatment through his patented inventions. His work continues to hold promise for improving patient outcomes in the fight against cancer.